A case of tardive dyskinesia (td) in a patient with non squamous cell carcinoma being treated with aripiprazole

Aripiprazole is an atypical antipsychotic that is usually well tolerated. It is FDA approved for treatment for schizophrenia and mania in Bipolar Disorder. Off label use includes augmentation protocols for depression and anxiety disorders as well as aggression in the pediatric population. Properties include 5-HT1A partial agonism and 5HT1-A antagonism along with D2 and D3 agonism. Abilify is often preferred due to reduced risk of metabolic syndrome, extrapyramidal symptoms and minimal sedative profile.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Poster Number: EI-51 Source Type: research